Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Other Non-Current Assets: 2010-2020

Historic Other Non-Current Assets for China Pharma Holdings (CPHI) over the last 5 years, with Jun 2020 value amounting to $222,996.

  • China Pharma Holdings' Other Non-Current Assets fell 55.69% to $222,996 in Q2 2020 from the same period last year, while for Jun 2020 it was $222,996, marking a year-over-year decrease of 55.69%. This contributed to the annual value of $109,908 for FY2019, which is 91.37% down from last year.
  • As of Q2 2020, China Pharma Holdings' Other Non-Current Assets stood at $222,996, which was down 32.64% from $331,038 recorded in Q1 2020.
  • China Pharma Holdings' Other Non-Current Assets' 5-year high stood at $2.6 million during Q2 2017, with a 5-year trough of $109,908 in Q4 2019.
  • Over the past 3 years, China Pharma Holdings' median Other Non-Current Assets value was $739,967 (recorded in 2019), while the average stood at $819,424.
  • In the last 5 years, China Pharma Holdings' Other Non-Current Assets surged by 104.92% in 2017 and then tumbled by 91.37% in 2019.
  • China Pharma Holdings' Other Non-Current Assets (Quarterly) stood at $1.1 million in 2016, then slumped by 34.81% to $709,796 in 2017, then surged by 79.48% to $1.3 million in 2018, then tumbled by 91.37% to $109,908 in 2019, then tumbled by 55.69% to $222,996 in 2020.
  • Its last three reported values are $222,996 in Q2 2020, $331,038 for Q1 2020, and $109,908 during Q4 2019.